Express News | Exact Sciences Corp : Bernstein Raises Target Price to $83 From $81
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights
Analysts' ratings for Exact Sciences (NASDAQ:EXAS) over the last quarter vary from bullish to bearish, as provided by 8 analysts.In the table below, you'll find a summary of their recent ratings,
Exact Sciences Is Maintained at Buy by Goldman Sachs
Exact Sciences Is Maintained at Buy by Goldman
Express News | Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $75
Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening
Since its launch in 2022, the FOCUS Program has awarded more than $4.5 million to over 75 organizations throughout the United StatesMADISON, Wis.--(BUSINESS WIRE)--Exact Sciences, a leading provider
Exact Sciences Corporation (EXAS) Slipped Over Investors' Concerns
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Exact Sciences Schedules Second Quarter 2024 Earnings Call
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S.
People Are Feeling Stuck in Their Jobs. Bosses Are Starting to Worry. -- WSJ
By Chip Cutter You are likely not getting a big promotion this year. So how about a job swap? Many workers say they are considering that question as they feel stuck in their roles. With the white-co
Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group
Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Exact Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 67.42% Evercore ISI Group $80 → $72 Maintains Outperform 06/27/2024 62.77% BTIG $80 → $70 Maint
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $72
Evercore analyst Vijay Kumar maintains $Exact Sciences(EXAS.US)$ with a buy rating, and adjusts the target price from $90 to $72.According to TipRanks data, the analyst has a success rate of 47.4% and
Express News | Geneoscopy: Confident Litigation Will Not Delay Commercial Launch of Colosense
Express News | Geneoscopy: Files Counterclaims Against Exact Sciences
Exact Sciences Initiated at Sector Outperform at Scotiabank on Advanced Diagnostics
Exact Sciences Initiated at Sector Outperform by Scotiabank
Exact Sciences Initiated at Sector Outperform by Scotiabank
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Jefferies analyst Tycho Peterson maintains $Exact Sciences(EXAS.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 55.3% and a
Scotiabank Initiates Exact Sciences at Sector Outperform With $70 Price Target
Exact Sciences (EXAS) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $66 to $100. Price: 44.00, Change: -0.16, Percent Change: -0.36
Express News | Exact Sciences Corp : Btig Cuts Target Price to $70 From $80